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Abstract
Background: Leptin changes brain structure, neuron excitability and synaptic plasticity. It also regulates the development
and function of feeding circuits. However, the effects of leptin on neurocognitive development are unknown.
Objective: To evaluate the effect of leptin on neurocognitive development.
Methodology: A 5-year-old boy with a nonconservative missense leptin gene mutation (Cys-to-Thr in codon 105) was
treated with recombinant methionyl human leptin (r-metHuLeptin) at physiologic replacement doses of 0.03 mg/kg/day.
Cognitive development was assessed using the Differential Ability Scales (DAS), a measure of general verbal and nonverbal
functioning; and selected subtests from the NEPSY, a measure of neuropsychological functioning in children.
Principal Findings: Prior to treatment, the patient was morbidly obese, hypertensive, dyslipidemic, and hyperinsulinemic.
Baseline neurocognitive tests revealed slower than expected rates of development (developmental age lower than
chronological age) in a majority of the areas assessed. After two years, substantial increases in the rates of development in
most neurocognitive domains were apparent, with some skills at or exceeding expectations based on chronological age. We
also observed marked weight loss and resolution of hypertension, dyslipidemia and hyperinsulinemia.
Conclusions: We concluded that replacement with r-metHuLeptin is associated with weight loss and changes in rates of
development in many neurocognitive domains, which lends support to the hypothesis that, in addition to its role in
metabolism, leptin may have a cognitive enhancing role in the developing central nervous system.
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Introduction
Leptin, the product of the ob gene, is an adipocyte-derived
hormone with multiple functions in reproduction [1,2], glucose
homeostasis [3,4], bone formation [5,6], tissue remodeling [7], and
inflammation [8],aswellasinother elementsof theendocrine [9,10]
and immune systems [11,12]. The most important function of leptin
is the regulation of energy expenditure and food intake, due to its
actions on the arcuate nucleus of the hypothalamus. In this area,
leptin binds to its respective receptors, which are expressed in two
different neuronal populations: those that express agouti-related
peptide (AgRP) and neuropeptide Y (NPY), and those that express
the peptide cocaine and amphetamine-related transcript (CART)
and the large precursor peptide pro-opiomelanocortin (POMC).
Leptin exerts anorexigenic effects by inhibiting the AgRP/NPY
neurons and by stimulating the POMC/CART neurons. Among
mice that are leptin-deficient (ob/ob) or leptin-resistant (db/db),
hyperphagia is a constant and obesity, a hallmark.
The effects of leptin on body composition, bone metabolism and
on immune, endocrine and metabolic parameters have already been
well documented. It has also been shown that treatment with leptin in
its synthetic form (recombinant methionyl human leptin; r-metHu-
Leptin) leads to structural [13] and functional changes within specific
regions of the central nervous system [14,15]. Other roles of leptin
within the brain include effects on neuron excitability and on synaptic
plasticity [16–18]. In addition, leptin maintains neural stem and
progenitor cells,affects neural differentiation, promotes the migration
of neuronal lineage cells to the cortical plate, and regulates the
development of hypothalamic feeding circuits [19–21]. Taking all
these actions together, it is feasible to hypothesize that leptin is also
important for the development of neurocognition. There is no data in
the literature addressing the effects of leptin on the development of
neurocognition in humans. The evaluation of these effects in normal
humans has many limitations, such as the ethical problems in
administering exogenous leptin to normal children and the fact that
the child’s endogenous leptin is an evident confounding factor.
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the only leptin-deficient patients identified at adulthood to date.
Concomitantly, we described the effects of leptin-replacement
therapy in these unique patients [13,14,22–25]. These patients are
two women and one man from a highly consanguineous extended
Turkish pedigree, who carry a nonconservative missense leptin
gene mutation (Cys-to-Thr in codon 105). These patients have
benefited from a daily injection of recombinant methionyl human
leptin (r-metHuLeptin) and have shown significant improvements
regarding body weight, gonadal function and behavior. To our
knowledge, 10 children with congenital leptin deficiency, also due
to loss-of-function mutations in the gene encoding leptin, have
been identified in the world [26–30].
Here we present a unique human model that overcomes the
limitations of administering exogenous leptin to normal children,
in order to evaluate its effects on cognition. We show, for the first
time, the effects of replacement with r-metHuLeptin on neuro-
cognition in a leptin-deficient boy from the aforementioned
consanguineous Turkish family. Additional data on the anthro-
pometric and metabolic parameters are described, before and
during treatment.
Methods
The protocol for this n-of-1 trial and supporting CONSORT
checklist are available as supporting information; see Protocol S1
and Checklist S1.
Patient
The patient is a 7-year-old male born to a highly consanguin-
eous Turkish family. His parents are first-degree cousins. Due to
excessive weight gain beginning at age 3 months, and to familial
history of leptin deficiency caused by a mutation in the leptin gene,
that gene was genotyped when he was 2 years old.
Genotyping
The nucleotide sequence of the ob gene was analyzed in the
proband and his first-degree relatives by direct sequencing. The
patient was homozygous for a missense leptin gene mutation (Cys-
to-Thr in codon 105), whereas the parents and the sister were
heterozygous for the same mutation.
Leptin administration and dose
Leptin replacement therapy was started at age 5y1m. Recom-
binant methionyl human leptin (r-metHuLeptin) was supplied
initially by Amgen, Inc. (Thousand Oaks, CA, USA), and
subsequently by Amylin Pharmaceuticals, Inc., (San Diego, CA,
USA). The drug has been uninterruptedly administered once a
day in the evening (18:00–20:00), with a starting dose of 1.36 mg/
day SQ. Dosage was initially calculated to achieve a peak serum
leptin concentration of 70 ng/ml, which is equivalent to 10% of
the child’s predicted normal serum leptin concentration (based on
age, sex, and body composition) [31,32]. Due to his decreased
food intake and subsequent weight loss, dosage was progressively
reduced to 0.45 mg/day, which is the current dose, at age 7y5m.
We chose daily evening administration to model the normal
circadian variation of endogenous leptin, which is characterized by
a pulsatile circadian rhythm with a marked nocturnal rise [33].
Neurocognitive evaluations
The patient underwent a neurocognitive evaluation pre-
treatment (T1, at age 5y1m) and twice following the initiation of
leptin treatment (T2, at age 6y0m; T3, at age 7y2m). A fluent
Turkish-speaking clinician who was familiar with all test items
translated the test instructions and language based measures. The
clinician was familiar to the patient and had established good
rapport. The patient generally showed interest in the tasks and
readily participated but showed inconsistent attention. In order to
maintain cooperation and interest in the test items, M&M candies
were offered as needed to the patient at the T1 and T2 test sessions
but were not necessary at T3.
The following neurocognitive assessments were administered: 1)
Differential Ability Scales (DAS), a measure of general verbal and
nonverbal functioning; and 2) selected subtests from the NEPSY, a
measure of neuropsychological functioning in children. Both
measures are standardized, commercially available instruments
that are used for clinical and research purposes. Although both the
DAS and the NEPSY are normed on a representative sample
based on the US population census and on English speaking
children only, careful consideration was given to selecting
instruments (and subtests from these instruments) that tap into
general skills and are least likely to be affected by cultural factors.
We are fully aware that language and cultural differences may
have introduced biases to the test results. Nonetheless, the
longitudinal design was a strength in the study as it allowed us
to use within subject analyses (with the patient’s pre-treatment
performance serving as his own control) to describe changes in
cognitive functioning after the initiation of leptin treatment.
Therefore, any aspects of culture or language status that may have
affected the test results would have a similar effect on the patient’s
performance at all three time points and therefore cancel out in
the analyses.
We assumed that the level of cognitive functioning at the pre-
treatment evaluation was representative of the patient’s cognitive
functioning from birth until the baseline evaluation. This
assumption seemed reasonable given that the effect of leptin on
brain development likely began in utero. Rates of development
were computed for each of the three sets of time points: T1) from
birth to 61 months (pre-treatment), T2) from 61 months to 72
months (one year post-treatment), and T3) from 72 months to 86
months (two years post-treatment). To assess changes in cognitive
functioning pre- and post-treatment, age equivalencies (based on
typical performance for a given age or age range) were derived
using normative data from the test manuals. For example, at age 4,
performance at the level of a 4-year-old would yield a rate of
development of 1 (4/4). Therefore, a ratio of ‘‘1’’ indicates typical
development. In contrast, at age 4, a performance at the level of a
3-year-old would yield a developmental rate of 0.75 (3/4).
Subsequently, a score of ,1 indicates performance (developmental
age) below that expected for chronological age. Rates above ‘‘1’’
indicate development above expected levels.
In addition to the cognitive measures, parent report measures
assessing behavioral/emotional problems (Achenbach Child
Behavior Checklist, CBCL) and behavioral regulation/executive
functioning (Behavioral Rating Inventory of Executive Function,
BRIEF) were orally translated and administered to the patient’s
mother.
Hormonal and metabolite assays
Blood samples were obtained after overnight fasting and
analyzed for TSH, free T4, T3, cholesterol, triglycerides, HDL
cholesterol, LDL cholesterol, glucose, and insulin, using standard
assays, at T1 and T3.
Food intake
At T1 and T2, the General Clinical Research Center at the
University of California, Los Angeles (UCLA GCRC) provided
food ad libitum. During these visits, intake was calculated by
Leptin in Cognition.
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initial content of each item served. All food and beverages
provided to the patient were recorded by weight (in grams, to
nearest 0.1 g) with a precision balance (Mettler-Toledo Inc.,
Columbus, OH). The patient’s mother was also instructed to keep
dietary records, which were carefully reviewed by the GCRC
Senior Dietician. Nutrient intake was calculated using a nutrition
analysis software (Nutritionist Pro, First DataBank, Inc., San
Bruno, CA). At T3, meals were not provided by the GCRC, as the
participant was evaluated as an outpatient. Nevertheless, he was
allowed to eat ad libitum, and dietary intake was assessed through
food records kept by his mother. The software Food Processor
SQL (Esha Research, Salem, OR, USA) was used for nutritional
analysis in 2007.
Research ethics
At T1 and T2, the study took place at the General Clinical
Research Center at the University of California, Los Angeles
(UCLA GCRC). The study protocol was approved by the Food
and Drug Administration and by the UCLA Institutional Review
Boards. At T3, the study site was relocated to the University of
Miami, where new approvals from the local Institutional Review
Boards were obtained. Informed parental consent/patient assent
(at age 7) were obtained for all studies. Written informed consent
for publication was given by the mother.
Results
Neurocognitive development
General cognitive ability was assessed by the DAS, which
measures verbal, nonverbal, short-term memory, and pre-
academic skills. The patient’s pre- and post- treatment DAS
verbal and nonverbal cluster scores were lower than the scores for
age- matched controls from the normative sample. However,
administration of r-metHuLeptin was followed by an upward
trend in development, with scores generally normalizing by T3.
Pre-treatment verbal and nonverbal scores were in the 4
th
percentile. At T2, verbal scores were in the 9
th percentile while
nonverbal scores were in the 6
th percentile. In contrast, by T3, the
patient’s verbal scores were in the 14
th percentile while his
nonverbal scores were in the 30
th percentile, both broadly within
normal limits for his age. With one exception (‘‘Recall of
Objects’’), Figure 1 reveals that the patient’s pre-treatment rate
of development was consistently lower than expected for all DAS
subtests administered. Of note however, the patient’s rate of
development increased, especially by T3, and in several instances
Figure 1. Rates of development for DAS subtests. A rate of ‘‘1’’ (vertical axis) indicates typical development (i.e., developmental age equals
chronological age). For example, at age 4, performance at the level of a 4 year old would yield a rate of development of 1 (4/4). In contrast, at age 4, a
performance at the level of a 3 year old would yield a developmental rate of 0.75 (3/4). Subsequently, a score of ,1 indicates performance
(developmental age) below that expected for chronological age.
doi:10.1371/journal.pone.0003098.g001
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close to ‘‘1’’).
Neuropsychological functioning was evaluated by the NEPSY,
with results analyzed similarly to those of the DAS (described in
Methods). Similar to his cognitive results, the patient’s intra-
treatment rate of development showed an increasing trend
compared to his pre-treatment rate of development, with many
T3 rates of development at or exceeding age expectations (e.g.,
Memory for Faces, Blocks). The NEPSY scores are illustrated in
Figure 2.
Parental report of emotional problems and behavioral regula-
tion resulted in scores that were within normal limits compared to
age-matched peers on all three occasions. The patient’s mother
did not report any concerns except for his overall health and well-
being.
Metabolic and anthropometric parameters
Ten months after initiation of therapy, his growth velocity was
normal (5.7 cm/year), but it decreased slightly to 4.1 cm/year,
when calculated between ages 5y11m and 7y2m. Figure 3 and
Table 1 illustrate the changes in anthropometric parameters.
On baseline clinical examination, the patient’s blood pressure
measured 110/70, slightly above the 90
th percentile for his age
[34]. At age 7y2m, his blood pressure was normal, at 101/
66 mmHg. Other vital signs were normal at all times and, besides
obesity, there were no other abnormalities. At baseline, the patient
had normal liver and renal functions and was euglycemic at all
times, but presented with hyperinsulinemia before treatment. This
was normalized as his weight started to decrease. Also, there were
decreases in triglycerides, total cholesterol and LDL cholesterol,
and an increase in HDL cholesterol. Thyroid function was normal
at all times (Table 2).
Caloric intake
Before treatment, average caloric intake was 2,7096370 kcal/
day (54.362.5% from carbohydrate, 32.661.6% from fat and
13.161.1% from protein). In the 4
th week of treatment, average
caloric intake decreased to 1,7516475 kcal/day (56.065.9% from
carbohydrate, 32.662.9% from fat and 11.563.2% from protein).
One year after treatment initiation, average daily caloric intake
was 2,5946346 kcal (55.865.6% from carbohydrate, 31.063.5%
from fat and 13.262.8% from protein). Two years after treatment
initiation, average daily caloric intake was 2,1946292 kcal
(64.563.12% from carbohydrate, 16.663.0% from fat and
15.165.16% from protein), which is 106% of the recommended
caloric intake for a boy this age, height and weight.
Discussion
In this n-of-1 trial, we observed that leptin was associated with
an improved rate of development in various aspects of neurocog-
nitive functioning. As evidence that leptin replacement was
beneficial to the patient, we documented resolution of hyperten-
sion, dyslipidemia and hyperinsulinemia, in the context of
decrease in food intake and weight loss. To the best of our
knowledge, this is the first longitudinal study that shows that leptin
has a cognitive enhancing role in the developing CNS of humans.
To achieve that result, we employed the only possible human
model: a leptin-deficient child under leptin replacement therapy.
Treatment of leptin-sufficient children poses many ethical issues,
and results are contaminated by the fact that these children are
already under the effects of their endogenous leptin. Due to the
leptin-naı ¨ve status of the patient, we were able to evaluate the
effects of leptin on the developing CNS.
To compute rates of development at different time points, we
inferred a steady rate from birth to 61 months (pre-leptin
treatment) because we did not have two pretreatment baselines.
The inferred rate of development was much slower from birth to
61 months (T1), suggesting developmental age below expectations
for chronological age, than the rate of development observed
during the treatment phase (T1 to T3) on most of the
neurocognitive measures administered. By T3 (two years after
initiation of leptin therapy), developmental relative chronological
age ratios increased on all but one subtest compared to the
baseline evaluation, and in many cases, approached or exceeded
chronological age expectations. Because the patient had not
experienced any environmental changes that would affect his
neurocognitive abilities (i.e., starting school, receiving tutoring)
between T1 and T2, we cautiously attribute the increased rate of
development to leptin treatment and its subsequent effects on the
CNS. However, the patient had completed the first year of school
in his home country by the time of the third evaluation, which may
partly have contributed to the apparent increase in rate of
development between T2-T3. Nonetheless, these improvements
Figure 2. Rates of development for NEPSY subtests. A rate of ‘‘1’’ (vertical axis) indicates typical development (i.e., developmental age matches
chronological age). A score of ,1 indicates performance (developmental age) below that expected for chronological age.
doi:10.1371/journal.pone.0003098.g002
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normalize certain brain structures in leptin deficient mice. It would
be instructive to compute correlations between rates of change in
cognitive scores and rates of change in brain volume pre- and post-
treatment to further support this assertion. Nonetheless, initial
results suggest that in this leptin deficient patient, leptin may have
had a cognitive enhancing role.
After the initiation of r-metHuLeptin, we observed a slower rate
of development at T2 relative to T1 on a few subtests (‘‘Recall of
Objects,’’ ‘‘Memory for Faces,’’ and ‘‘Blocks’’). However, scores at
T2 were no more than 20% lower than scores predicted for age
and in most cases, not clinically different. The few exceptions to
the general pattern of increase in developmental rate may in part
be within the error variance of the instrument. These normal
variations in performance are difficult to characterize given that
there is only subject in the study.
Leptin has a role in the central nervous system beyond its
regulatory function through the hypothalamus on food intake and
energy balance. Leptin is expressed in the brain, including the
cerebellum, pyriform cortex, cerebral cortex, thalamus, hippocam-
pus, amygdala, olfactory tract and substantia nigra [35]. It may
improve cognition by the selective enhancement of N-methyl D-
aspartate (NMDA) receptors, facilitating long-term potentiation
(LTP) [36]. In low frequency stimulation, leptin inhibits hippocam-
pal neurons, regulating hippocampal excitability [35,37]. In adult
mice,leptinincreaseshippocampalneurogenesis,bothinvitroandin
vivo[38]. Hippocampal synaptic plasticity is also regulated by leptin.
Animals with leptin receptor mutations (db/db mice or fa/fa rats)
present deficits in hippocampal-specific memory tasks [39],
impairments in hippocampal LTP, and long-term depression [36].
Leptin is also an important hormonal signal in the developing CNS.
In adult leptin deficient (ob/ob)o rl e p t i nr e s i s t a n t( db/db) mice, for
example, leptin deficiency leads to lower brain weight and protein
content [21,40,41]. Many of these effects normalize after postnatal
administration of leptin [35]. In addition, brain myelin [42],
neuronal soma size [43], and several synaptic proteins are reduced
[35]. Growth-associated proteins in the neocortex, striatum and
hippocampus are elevated, and dendritic orientation is altered [44].
In humans, normal neonates have two to three times higher
serum leptin levels, when compared to adults [45]. Elevated
circulating leptin levels are originated from the maternal and the
neonatal adipose tissue, as well as from the placenta. Moreover,
the increased adipose leptin mRNA expression in fetal adipose
tissue, and the delayed onset of synthesis of leptin prior to the
maturation of its receptor also explain the high levels of leptin
[46]. Several maternal, placental and neonatal factors are
potentially associated with production and functions of leptin in
early life, and have been reviewed by Alexe et al. [47]. Leptin does
not appear to regulate food intake and body weight during
neonatal life [48], and the metabolically irrelevant surge of leptin
may act as a developmental signal [49], which coincides with the
development of major hypothalamic feeding circuits [50]. This
Figure 3. Patient before replacement with r-metHuLeptin at
age 5y1m and during treatment at age 7y2m.
doi:10.1371/journal.pone.0003098.g003
Table 1. Weight, height and BMI before and after treatment initiation, correlated with percentiles for same sex and age.
5y1m 5y11m 7y2m
Before treatment initiation (T1) 10 months after treatment initiation (T2) 25 months after treatment initiation (T3)
Weight (percentile for age) 47.0 kg (.97
th percentile) 32.3 kg (.97
th percentile) 33.7 kg (97
th percentile)
Height (percentile for age) 109 cm (50
th percentile) 114 cm (50
th percentile) 119 cm (25
th percentile)
BMI (percentile for age) 39.6 kg/m
2 (.97
th percentile) 24.8 kg/m
2 (.97
th percentile) 23.8 kg/m
2 (.97
th percentile)
doi:10.1371/journal.pone.0003098.t001
Table 2. Lipid profile, glucose and insulin before and after
treatment initiation.
T1 T3
Glucose (mg/dl) 79 87
Insulin (uU/ml) 21 7
Cholesterol (mg/dl) 166 155
LDL (mg/dl) 87 66
HDL (mg/dl) 36 65
Triglycerides (mg/dl) 216 120
TSH (mU/l) 3.8 4.57
Free T4 (ng/dl) 1.3 1.2
T3 (ng/dl) 154 167
doi:10.1371/journal.pone.0003098.t002
Leptin in Cognition.
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of maximum sensitivity, corresponding to a period of elevated leptin
secretion [51]. However, in adults, leptin can still affect brain
plasticity by causing synaptic rearrangement of excitatory and
inhibitory inputs on arcuate neurons [18], suggesting that these
circuits remain relatively plastic throughout life.
In abnormal conditions, low levels of leptin at birth are seen in
small for gestational age infants [52], but the neurodevelopmental
consequences of this alteration have not been evaluated. The
neurodevelopmental actions of leptin are not restricted to the
hypothalamus: it has been demonstrated that cortical and
hippocampal development can also be influenced by leptin
[53,54]. It is known that, besides its effects on the components
of feeding circuits, leptin also acts as a cognitive enhancer in the
hippocampus and on excitatory synaptic strength, which may
regulate the processes involved in learning and memory [17,36].
These processes would be explained, at the cellular level, by the
leptin-mediated modulation of hippocampal synaptic plasticity,
leading to the conversion of hippocampal short-term potentiation
(STP) into LTP, via enhancing NMDA receptor function [55]. In
the hippocampus, leptin also regulates neuronal excitability via its
ability to activate the large conductance Ca
2+-activated K
+ (BK)
channels. Leptin can also evoke a novel form of NMDA receptor-
dependent LTD in the CA1 region of the hippocampus, but this is
only apparent under conditions of enhanced excitability [56,57].
The signaling processes underlying these effects involve activation
of a phosphatidylinositol 3-kinase-dependent process [35]. Acti-
vation of mitogen-activated protein kinases and Src tyrosine
kinases has also been implicated in this pathway.
Morphological studies in adult humans with genetic leptin
deficiency suggest that leptin effect on the CNS extends beyond
the hypothalamicnuclei.Sixmonthsofleptinreplacementtreatment
for these three genetically leptin-deficient adults produced increased
gray matter concentration in the anterior cingulate gyrus, inferior
parietal lobule, and the cerebellum, findings that were maintained
for 18 months following treatment [13].
The mostmarked effectof leptinreplacement isweight loss, which
is primarily achieved through reducing caloric intake. Leptin also
leads to weight loss by increasing resting energy expenditure (REE)
in animals [58], but not in humans [29]. In this study, we did not
evaluate the effects of leptin on REE, which prevents us from stating
that weight loss was entirely attributed to the decrease in energy
intake. Following weight loss, we observed a mild deceleration in
growth. Height changed from the 50
th percentile to the 25
th
percentile between the first and the second year under treatment.
Growth will be monitored and adequate hormonal parameters will
be assessed in the next follow-up visit. Subsequent to losing weight,
hypertension, dyslipidemia and hyperinsulinemia were reversed. We
believe these changes are attributable to weight loss, but we cannot
exclude a direct effect of leptin on these parameters, independent of
weight loss. In particular, it is known that leptin directly affects the
pancreatic beta cells to decrease insulin secretion [59], but it is
problematic to evaluate whether these changes are caused by leptin
alone, by weight loss or both.
We acknowledge that our study has some limitations. First, the
significance of our findings is hard to judge, due to the fact that we
report the findings on only one patient. To our knowledge, eleven
leptin-deficient children have been identified in the world thus far
(including our patient). Neurocognitive evaluations of these
children are warranted, preferably at early ages, and while
leptin-naı ¨ve. Second, we did not have an age-, sex-, weight- and
cultural background-matched control group. To compensate for
this limitation, we gave careful consideration to our choice of
measurement instruments so as to select tests and subtests that are
less culturally biased and measure general skills. Further, we
considered a strength of the study to the fact that we have
longitudinal evaluation, which in essence allowed us to use the
patient’s baseline performance as his own control for subsequent
evaluations. Although this is an n-of-1 trial, we chose not to
conduct additional leptin-free evaluations (other than those
performed at T1) because we believe that the absence of leptin
would be harmful to the child’s development.
In conclusion, treatment of a leptin-deficient child with r-
metHuLeptin was beneficial, leading to improvements in neuro-
cognition, substantial weight loss, decrease in caloric intake and
normalization of the parameters of metabolic syndrome. Further
studies need to confirm these neurocognitive findings additional in
leptin-deficient patients across the life span. Additional findings
may support a rationale for the development of further studies to
test the hypothesis that the effects of leptin replacement may
improve cognition in leptin-sufficient patients with delay or decline
of cognitive function.
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